News

Draft ICER Report Questions Cost-Effectiveness of New Migraine Drugs

Draft ICER Report Questions Cost-Effectiveness of New Migraine Drugs

The Institute for Clinical and Economic Review has published a draft report on the cost-effectiveness of three soon to be launched migraine drugs. ICER used expected pricing numbers in its evaluation and found that triptans would “provide a greater benefit at a lower total cost” for patients who respond to them, however, the new drugs would benefit those that do not respond to the existing treatments. As the only integrated premium courier service provider, Yourway supports new drug development and relies on our team of highly experienced project managers to oversee supply chain management worldwide.

Back to Index
Media

Upcoming Event

IQPC CTS

August 24-26, 2020
Brussels, Belgium

Media

Articles

The New Normal in Clinical Trial Protection

Open chat
Come chat with us!
Hello! How can I help you?